Class II
Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Berkley Heights, NJ 07922, NDC 51991-747-10.
CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
- Recall number
- D-0308-2025
- Report date
- April 9, 2025
- Classification
- Class II
- Status in dataset
- Ongoing
- Recalling firm
- Breckenridge Pharmaceutical, Inc.
- Generic names
- DULOXETINE HYDROCHLORIDE
- Brand names
- DULOXETINE
- Product NDCs
- 51991-746, 51991-747, 51991-748, 51991-750
Code and lot information
Lot 240909C, Exp Date 03/31/2027
Distribution
Nationwide in the US
Do not stop or change a prescribed medication based only on this page.Contact your pharmacist or prescriber and compare the exact product, manufacturer, NDC, and lot information.
Source and limitations
This page reflects a public openFDA Drug Enforcement record. The dataset was last checked on September 23, 2026. openFDA states that enforcement data should not be used alone to issue public alerts or track the full lifecycle of a recall.
Review the official FDA Drug Recalls page and the underlying openFDA query.